Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors

NCT01286987 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01286987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01286987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
January 3, 2011
Completion date
January 30, 2017
Enrollment
113 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or recurrent solid tumors, breast neoplasms, ewing sarcoma, ovarian cancer, epithelial, pancreas cancer, prostate cancer, small cell lung carcinoma